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Background. In patients admitted with chest pain and suspected acute coronary syndrome (ACS), it is crucial to early identify those
who are at higher risk of adverse events. The study aim was to assess the predictive value of copeptin in patients admitted to the
emergency department with chest pain and nonconclusive ECG. Methods. Consecutive patients suspected for an ACS were
enrolled prospectively. Copeptin and high-sensitive troponin T (hs-TnT) were measured at admission. Patients were followed
up at six and 12 months for the occurrence of death and major adverse cardiac and cerebrovascular events (MACCE). Results.
Among 154 patients, 11 patients died and 26 experienced MACCE. Mortality was higher in copeptin-positive than copeptin-
negative patients with no difference in the rate of MACCE. Copeptin reached the AUC 0.86 (0.75–0.97) for prognosis of
mortality at six and 0.77 (0.65–0.88) at 12 months. It was higher than for hs-TnT and their combination at both time points.
Copeptin was a strong predictor of mortality in the Cox analysis (HR14.1 at six and HR4.3 at 12 months). Conclusions.
Copeptin appears to be an independent predictor of long-term mortality in a selected population of patients suspected for an
ACS. The study registration number is ISRCTN14112941.
1. Introduction
The optimal risk stratification in patients with acute coronary
syndrome (ACS) without persistent ST segment elevation is a
priority for clinicians. Patients after an ACS remain on
higher risk of the development of heart failure, further ische-
mic events, and death. It is crucial to identify possibly early
those subjects who present with chest pain and are at higher
risk, in order to enable the introduction of adequate strategy
in optimal time frames. The guidelines for diagnosis and
treatment of non-ST segment elevation ACS focus attention
on early stratification of short- and long-term risk [1].
However, cardiac troponin (cTn), despite being the gold
standard marker for diagnosis of myocardial injury, remains
suboptimal in terms of early risk assessment. Due to the char-
acter of the release profile, repetitive blood sampling for cTn
is needed to achieve satisfactory prognostic accuracy [2]. The
introduction of high-sensitive assays allowed earlier stratifi-
cation of patients but did not justify single measurement or
risk stratification based solely on these assays. While looking
for complemental markers that would increase the accuracy
of cTn, we face a large variety of biomarkers [3]. It is of
utmost importance from a practical point of view to indicate
those that could be used for diagnostic and prognostic pur-
poses simultaneously as early as possible after symptom
onset. Copeptin, the C-terminal part of the prohormone for
vasopressin, is a marker of acute endogenous stress, with
rapid release pattern [4]. Several previous studies showed
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its good diagnostic accuracy in patients with an ACS [5–7].
Its potential prognostic role was described in patients with
the history of an acute myocardial infarction (AMI) who
developed heart failure [6, 8]. The strategy of combined use
of copeptin and cTn, besides serving as a diagnostic tool,
could identify patients with chest pain at higher risk for
adverse events and the development of heart failure (HF)
very early after symptom onset, thus enabling early triage
decision. Despite the combination of copeptin and high-
sensitive Tn (hs-Tn) was extensively described in terms of
diagnosis of an ACS, there is insufficient data regarding its
prognostic accuracy, especially in patients without persistent
ST segment elevation. We therefore aimed to investigate if
copeptin provides information on the prediction of outcome
in patients admitted to tertiary cardiac centers with symp-
toms of ACS and nonconclusive ECG.
2. Methods
The Copeptin for Acute Coronary Syndrome (COPACS) is a
prospective, investigator-initiated, observational study with
the aim to evaluate the role of copeptin in the diagnostic
and prognostic process in patients with acute chest pain to
enhance rapid evaluation in the emergency department.
Details on the design and the chart of the study were
widely described previously [9]. In brief, consecutive patients
presenting to the emergency department of the 2nd Depart-
ment of Cardiology in Zabrze, Medical University of Silesia,
Katowice, Poland, were screened in 24/7 manner. Patients
with chest pain lasting 5 minutes or more during the last 6
hours and the absence of persistent ST segment elevation in
admission ECG were prospectively enrolled to the study.
Major conditions with proved influence on copeptin eleva-
tion were regarded as exclusion criteria (e.g., end-stage renal
disease, sepsis, anaemia, and hyponatremia). According to
the tertiary character of the enrolling center, patients admit-
ted to the emergency department conform a highly prese-
lected population, referred mainly via regional hospital. In
the structure of our health care system, high rate of patients
with chest pain and without persistent ST segment elevation
on ECG undergoes initial stratification in regional hospitals.
Therefore, patients are referred and admitted to tertiary car-
diac centers after initial qualification to invasive coronary
angiography with longer delays from chest pain onset and
high suspicion of an ACS. As an effect, first, vast majority
of patients present later than six hours after chest pain onset
and, second, high rate of patients is finally diagnosed with
acute coronary syndrome.
The study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki as reflected in a priori
approval by the Ethical Committee of Medical University
of Silesia (decision number KNW/0022/KB1/187/11). All
patients gave their written informed consent before
inclusion to the study. The study registration number
is ISRCTN14112941.
The design of the study, data gathering, and analysis were
conducted according to the STARD guidelines for studies of
diagnostic/prognostic accuracy. All authors contributed to
the work by participating in the design, collecting and
analyzing the data, and writing the paper, and all accepted
the final draft of the manuscript.
After inclusion, each patient underwent initial clinical
examination which included physical examination, 12-lead
electrocardiogram (ECG), echocardiographic examination,
and standard laboratory tests (blood count, sodium, potas-
sium, creatinine, GFR, C-reactive protein [CRP], and N-
terminal pro-B type natriuretic peptide [NT-proBNP]).
Hs-TnT, creatine kinase myocardial bound (CK-MB), and
copeptine were measured at admission (T0). Copeptin was
double-blinded until final adjudication of the diagnosis.
Hs-TnT and CK-MB were afterwards measured at six hours
(T6) and repeated according to clinical indications.
Initial diagnosis was set by the emergency physician and
was verified by a supervisor cardiologist based on available
data and the ESC guidelines [1]. All patients were stratified
according to the GRACE 1.0 risk score.
Further, all included patients underwent routine diagnos-
tic and therapeutic procedures as indicated in the ESC guide-
lines for non-ST segment elevation ACS [1] and according to
the study design [9]. Final diagnosis of non-ST elevation
myocardial infarction (NSTEMI), unstable angina (UA), or
other causes of chest pain was set based on independent
opinions of two cardiologists, after analysis of all available
data and tests gathered during the hospital stay. In case of
incoherence of their diagnosis, a third cardiologist was asked
for opinion.
Copeptin was measured once, at admission (T0) from the
blood sample managed according to the instructions of the
manufacturer of the test. The measurement was performed
using the BRAHMS Copeptin KRYPTOR kit on BRAHMS
KRYPTOR compact plus analyzer (BRAHMS GmbH, Hen-
nigsdorf, Germany)—detection limit at 4.8–500 pmol/l, 20%
coefficient of variation (CV) at 12 pmol/l, and the 97.5th per-
centile for healthy population at 17.4 pmol/l. According to
the general rule for the optimal cutoff for a marker at the
99th percentile of healthy population, copeptin was regarded
as positive when ≥17.4 pmol/l, following available informa-
tion provided by the manufacturer on the most compliant
value (97.5th percentile) to that recommended in the guide-
lines [1, 10]. For secondary analysis, the concentration of
10 pmol/l was used as a cutoff [10].
Troponin T was measured at admission (T0), after 6
hours from admission (T6), and at further time points
according to the decision of treating physician. Troponin
T was measured using an Elecsys Troponin T hs STAT kit
on a cobas e 411 analyzer (Roche Diagnostics GmbH,
Mannheim, Germany) with a high-sensitive electrochemilu-
minescence method (limit of detection 3–10,000 ng/l, 99th
percentile for healthy population 14ng/l [95% CI 12.7–
24.9 ng/l], and 10% CV 3ng/l). Hs-TnT was regarded as
positive when ≥14 ng/l, according to the manufacturer’s
indications and the guidelines [1].
The observational data of all patients were analyzed after
six months and one year. Six-month follow-up was con-
ducted in a phone call with the patient, relatives, or primary
care physician and included the information on Canadian
Cardiovascular Society (CCS) class, New York Heart Associ-
ation (NYHA) class, and the occurrence of endpoints. At one
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year, during a visit in the outpatient unit, following data were
gathered: CCS and NYHA classes, the occurrence of end-
points, echocardiogram with the assessment of EF, and blood
draw for NT-proBNP.
Primary endpoint was defined as death of cardiovascular
origin. Secondary endpoints were major adverse cardiac and
cerebrovascular events (MACCE) combined with death of
cardiovascular origin, nonfatal AMI, UA, repeated cardiac
revascularization, and stroke. Patients were also screened
for the occurrence of major bleeding.
Maximal hs-TnT/CK-MB was the maximal concentra-
tion of the biomarker measured during the hospital stay.
Smoker was regarded as past if one was free of smoking for
at least one year before admission. Familial history of coro-
nary artery disease was positive if AMI, stroke, or cardiac
death occurred in at least one first-degree female relative at
the age of <55 years or male relative at the age of <65 years.
Coronary artery disease was diagnosed in coronary angio-
gram if the stenosis of coronary artery was >75% (or >50%
for left main).
Data were checked for normality of distribution with the
Shapiro-Wilk test. Continuous variables are presented as
mean, standard deviation (SD), or median (interquartile
range [IQR]) and were compared with the Student t-test or
Mann–Whitney test and ANOVA or Kruskal-Wallis test,
depending on their distribution. Categorical variables are
presented as n (%) and were compared with chi-square test.
The correlation between copeptin and other parameters
was assessed with Spearman’s method. To evaluate the prog-
nostic accuracy, the receiver operating characteristic (ROC)
curves with areas under the curve (AUC) were used and com-
pared with the z test. Survival curves for copeptin and hs-
TnT were performed with the Kaplan-Meier method. The
influence of biomarkers and preselected baseline, clinical,
and procedural parameters on the occurrence of endpoints
was calculated in the Cox proportional hazard regression
model. The taxonomic analysis (focus analysis) was used as
a supplementary method to analyze prognostic accuracy in
a multivariate manner and is described in online Supplemen-
tary Material 1. The p value of <0.05 was assumed significant
throughout all analyses. All analyses were performedwith Sta-
tistica software, version 10PL (StatSoft Inc., Tulsa, OK, USA);
GraphPadPrism, version 6.00 (GraphPad, La Jolla, California,
USA); and platform R, version 3.0.2 (R Foundation for Statis-
tical Computing, Vienna, Austria).
3. Results
During the study period, a total of 1665 were screened. After
exclusion of 424 patients presented with STEMI and 1241
patients due to other exclusion criteria (40 patients with
anaemia, 31 with hyponatremia, 13 with laboratory errors,
995 patients with chest pain out of inclusion criteria, and 8
patients due to withdrawal of the informed consent), a total
of 154 patients were enrolled to the study. Mean age of the
population was 63, SD was 12 years, and 65% were male.
After adjudication of the final diagnosis, 105 patients (68%)
were diagnosed with NSTEMI, 30 patients (20%) were diag-
nosed with UA, and 19 patients (12%) presented other causes
of chest pain. Mean GRACE risk score was 124 (104–147) for
the population. Copeptin was positive in 48 patients (31%)
with the median of 11.56 (5.67–21.61) pmol/l.
Patients positive and negative for copeptin had a sim-
ilar clinical profile. Groups differed significantly with age;
patients were older in the copeptin-positive group. Regard-
ing the risk profile, patients positive for copeptin had higher
hs-TnT concentrations measured at every time point; higher
six-hour and maximal concentration of CK-MB; higher
admission NT-proBNP, CRP, and leukocytosis and lower
GFR; and higher GRACE risk score. Patients with positive
copeptin result had similar procedural characteristics and
received equal medical therapy as copeptin-negative patients
with significant differences with regard to in-hospital
catecholamine administration, more frequent in copeptin-
positive patients. Results are summarized in Table 1. Similar
results were observed for patients positive and negative for
copeptin with the cutoff 10pmol/l and are presented in
Supplemental Table S1.
Positive correlation of copeptin was found with age
(r = 0 36 [0.18–0.52]), maximal hs-TnT (r = 0 24 [0.05–
0.42]), six-hour and maximal CK-MB (r = 0 34 [0.16–0.5]
and r = 0 35 [0.17–0.51], resp.), leukocytosis (r = 0 36
[0.18–0.52]), and the GRACE risk score (r = 0 48 [0.32–
0.62]). Negative correlation reached statistical significance
with GFR (r = −0 27 [−0.44; −0.08]) and EF (r = −0 3
[−0.46; −0.11]).
Follow-up was completed in 98% of patients at six
months and 95% of patients at one year. Overall, 11 patients
died (8%) and 26 (18%) experienced MACCE (11 deaths, 3
AMI, 10 PCI, and 2 strokes). No major bleeding was reported
during the follow-up. Patients who died had significantly
higher concentrations of copeptin than survivors (103 [21–
168] pmol/l versus 11 [5.3–20] pmol/l, resp., p = 0 001), while
there was no statistically significant difference in copeptin
level between patients who experienced MACCE and other
patients (17 [6.0–52] pmol/l versus 11 [5.4–20] pmol/l, resp.,
p = 0 19).
At one year, copeptin-positive patients had higher NT-
proBNP concentrations than copeptin-negative patients
(216 [140–457] pg/ml versus 147 [80–359] pg/ml, p=0.049).
They also had higher NYHA class with more patients in
class III (20% versus 8%) and less in class I (50% versus
68%) than copeptin-negative patients (p = 0 014). Concentra-
tions of NT-proBNP remained higher in copeptin-positive
than in copeptin-negative patients when the cutoff 10pmol/l
was used (250 [118–567] pg/ml versus 135 [77–227] pg/ml,
p = 0 003), and no statistically significant difference was
observed in NYHA class between both groups (p = 0 10).
According to Kaplan-Meier analysis, patients with nega-
tive copeptin levels had significantly better survival than
copeptin-positive patients at six months (103/104 versus
41/47 patients, p = 0 001) and one year (98/102 versus 38/
45 patients, p = 0 011) (Figure 1(a)). After dichotomization
with the cutoff 10 pmol/l, similar results were observed at
six months (69/71 versus 67/76, p = 0 033) and one year
(71/71 versus 73/80 patients, p = 0 011) (Supplemental
Figure S1). No statistically significant difference in survival
was observed regarding hs-TnT levels throughout the
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(n = 48) p value
Baseline parameters and medical history
Age (years) 63 (57–73) 62 (56–69) 65 (57–78) 0.04
Male sex 100, 65% 72, 65.5% 28, 58.3% 0.25
BMI (kg/m2) 28.7 (42.9–32.3) 28 (25–32) 29 (25–32) 0.93
CAD 67, 44% 50, 45.5% 17, 35.4% 0.17
Hypertension 114, 74% 75, 68.2% 39, 81.3% 0.17
Diabetes mellitus 42, 27% 28, 25.5% 14, 29.2% 0.72
PAD 4, 2.6% 3, 2.7% 1, 2.1% 0.79
Familial history of CAD 21, 14% 18, 16.4% 3, 6.3% 0.07
Current smoker 51, 33% 38, 34.5% 13, 27.1% 0.28
Past smoker 31, 20% 23, 20.9% 8, 16.7% 0.47
Dyslipidemia 67,44% 49, 44.5% 18, 37.5% 0.31
History of AMI 46, 30% 36, 32.7% 10, 20.8% 0.10
History of PCI 48, 31% 36, 32.7% 12, 25.0% 0.27
History of CABG 7, 4.5% 7, 6.4% 0, 0% 0.07
History of stroke 4, 2.6% 3, 2.7% 1, 2.1% 0.79
Baseline clinical status
Heart rate (beats/min) 75 (66–88) 70 (65–80) 75 (70–85) 0.07
Systolic BP 140 (123–160) 140 (125–160) 140 (120–160) 0.54
EF (%) 55 (45–60) 55 (45–60) 55 (43–60) 0.56
NYHA class III or IV 4, 2.6% 1, 0.9% 3, 6.3% 0.06
Killip class 0.50
1 139, 90% 98, 89.1% 41, 85.4%
2 14, 9.1% 7, 6.4% 7, 14.6%
3 1, 0.6% 1, 0.9% 0, 0%
4 0, 0% 0, 0% 0, 0%
GRACE 124 (104–146) 120 (101–141) 131 (111–167) 0.03
Laboratory parameters
Hs-TnT T0 (ng/l) 33 (13–143) 25 (11–125) 68 (30–177) 0.01
Hs-TnT T6 (ng/l) 75 (16–397) 32 (13–247) 234 (43–2284) <0.001
Hs-TnT max (ng/l) 105 (23–530) 52 (17–274) 236 (74–2070) <0.001
CK-MB T0 (IU/l) 20 (15–30) 19 (14–28) 22 (17–36) 0.06
CK-MB T6 (IU/l) 21 (14–45) 18 (13–32) 33 (18–107) <0.001
CK-MB max (IU/l) 27 (18–53) 25 (17–42) 42 (25–111) <0.001
NT-proBNP (pg/ml) 350 (163–1074) 289 (150–872) 491 (223–1979) 0.02
CRP (mg/l) 2.9 (1.3–5.5) 3 (1–5) 4 (2–7) 0.03
Leukocytosis (103/μl) 8.4 (6.9–10.3) 8 (6–9) 10 (8–12) <0.001
Hemoglobin (g/dl) 14 (13–15) 14 (13–15) 14 (13–15) 0.34
GFR (ml/min/1.73m2) 92 (76–110) 93 (77–115) 90 (67–99) 0.08
In-hospital parameters
Diagnosis of CAD 116, 75% 83, 75.5% 33, 68.8% 0.11
Medical therapy 38, 25% 25, 22.7% 13, 27.1% 0.64
PCI 90, 58% 60, 54.5% 30, 62.5% 0.49
CABG 33, 21% 25, 22.7% 8, 16.7% 0.33
Catecholamines 4, 2.6% 0, 0% 4, 8.3% 0.003
ASA 141, 92% 97, 88.2% 44, 91.7% 0.79
DAPT 99, 64% 68, 61.8% 31, 64.6% 0.96
β-Blocker 134, 87% 93, 84.5% 41, 85.4% 0.81
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follow-up (p = 0 10 and p = 0 14 at six months and one year,
resp.) (Figure 1(b)).
Copeptin achieved a good prognostic accuracy in the
ROC analysis at six months (AUC 0.86 [0.75–0.97],
p < 0 001) and one year (AUC 0.77 [0.65–0.88], p = 0 003).
It was higher when compared to hs-TnT and their combina-
tion at six months (0.62 [0.53–0.72], p = 0 002, versus 0.76
[0.53–0.99], p = 0 42, resp.) and one year (0.63 [0.52–0.75],
p = 0 12, versus 0.63 [0.43–0.83], p = 0 24, resp.). Of note,
the ROC analysis of hs-TnT did not reach statistical signifi-
cance for the prediction of death at any time point. Addi-
tional analysis with the GRACE risk score for six-month
prediction of death revealed that copeptin was not inferior
to the GRACE risk score alone (0.86 [0.75–0.97] versus
0.96 [0.92–1.0], p = 0 09), and the highest AUC across all
analyzed factors for six-month mortality was observed for
the combination of copeptin with the GRACE risk score
(0.98 [0.95–1.0], p < 0 001). It outperformed both of the pre-
dictors alone (p = 0 04) and hs-TnT (p < 0 001).
In the Cox regression analysis, patients with copeptin
level≥ 17.4 pmol/l were at significantly higher risk of death
at six months (hazard ratio (HR) 14 (1.7–117), p = 0 014)
and at one year (HR 4.32 [1.27–14.77], p = 0 02). Contrary,
copeptin level≥ 10 pmol/l was not a significant risk factor
for death at six months (HR 61 [0.1–26.86], p = 0 19) nor at
one year (HR 4.56 [0.99–21.11], p = 0 052). Hs-TnT mea-
sured at admission was not a predictor of mortality in the
Cox analysis, neither was maximal concentration of hs-
TnT. Statistical significance for the prediction of mortality
was reached by age (HR 1.1 [1.04–1.18], p = 0 002) and
GFR (HR 0.92 [0.89–0.95], p < 0 001). Detailed results are
presented in Table 2. The combination of higher copeptin/
older age/lower GFR identified a group with higher admis-







(n = 48) p value
ACE inhibitor 126, 82% 91, 82.7% 35, 72.9% 0.07
Statin 135, 88% 95, 86.4% 40, 83.3% 0.26
Diuretic 45, 29% 31, 28.2% 14, 29.2% 0.97
Ca-blocker 39, 25% 27, 24.5% 12, 25.0% 0.98
Nitroglycerin 17, 11% 12, 10.9% 5, 10.4% 0.89
Final diagnosis
Unstable angina 30, 20% 27, 24.5% 3, 6.3% 0.005
NSTEMI 105, 68% 65, 59.1% 40, 83.3% 0.007
Data presented as n, %, or median (25th–75th interquartile range). ACE: angiotensin-converting enzyme; AMI: acute myocardial infarction; ASA: acetylsalicylic
acid; BMI: body mass index; BP: blood pressure; CABG: coronary artery bypass grafting; CAD: coronary artery disease; CK-MB: creatine kinase myocardial
bound; CRP: C-reactive protein; DAPT: dual antiplatelet treatment; EF: ejection fraction; GFR: glomerular filtration ratio; GRACE: Global Registry for Acute
Coronary Events; Hs-TnT: high-sensitive troponin T; NSTEMI: non-ST segment elevation myocardial infarction; NT-proBNP: N-terminal pro-B-type
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Figure 1: Survival curves or copeptin (a) and hs-TnT (b). Hs-TnT: high-sensitive troponin T.
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ejection fraction, and higher risk according to the GRACE
risk score (Supplemental Table S2).
4. Discussion
This prospective, observational study assessed the prognostic
role of copeptin and its combination with hs-TnT in consec-
utive patients with acute chest pain admitted to the emer-
gency department of a tertiary cardiologic center.
The first finding is the high prognostic accuracy of
copeptin in the prediction of mortality. According to previ-
ously published data [11, 12], we report higher mortality in
patients with higher plasma levels of copeptin. Secondly,
copeptin had significantly better prognostic accuracy than
hs-TnT in studied population. There was no benefit from a
combined use of copeptin and hs-TnT over copeptin alone.
Thirdly, copeptin should be considered together with other,
but still simple risk factors, especially age and renal function,
while assessing prognosis. Lastly, we provide indirect evi-
dence for the significant prognostic value of copeptin in the
prediction of HF at long-term assessed with NT-proBNP,
a recently strongly recommended diagnostic parameter of
HF [13].
The prognostic value of copeptin in patients with chest
pain is the field of research interest and constant growth.
In this study, we add evidence on prognostic utility of
copeptin as an early marker of adverse outcome in a specific
population of highly preselected patients with high rate of
finally diagnosed ACS, characteristic for tertiary centers.
The decision on optimal type and time frame of the man-
agement is essential for non-ST segment elevation ACS
and appropriate selection of patients in whom invasive
interventions are likely to be beneficial. According to the
guidelines [1], the triage of patients in such circumstances
should be extensive; involve clinical status of patients, med-
ical history, the dynamics of ECG, and biomarker concen-
trations; and be supported by different risk scoring
systems, for example, the GRACE risk score. Despite the
GRACE risk score is a validated tool in risk stratification
[14], the practical utility is compromised in everyday clinical
practice [15]. We provide evidence that supports very early
risk assessment with single measure from a blood draw at
admission. The results of the Cox analysis identified copep-
tin, age, and renal dysfunction as risk markers of poor prog-
nosis at one year. Whether this combination of risk factors
would play a wide practical role remains to be determined
in a larger cohort.
The single measurement of copeptin at admission
showed also a tendency to increase the prognostic accuracy
of the GRACE risk score for death at six months. It confirms
previous reports on good prognostic performance of copep-
tin in the prediction of death, however assessed in different
clinical setting including STEMI [16] or derived from mea-
surements at later time points [6]. Nevertheless, these results
might serve as a background for further research on a simple
and concise prognostic evaluation methodology, which
would be of clinical benefit at the bedside, without the need
for extensive, repetitive examinations or online calculations.
The combination of copeptin and hs-TnT merits consid-
eration. The estimation of prognosis based on combined use
of copeptin and hs-TnT was not clinically relevant. Surpris-
ingly, hs-TnT alone was also not a significant predictor of
long-term death. It is known that cTn directly correlates with
infarct size [17] and the predictive value of cTn is higher for
maximal concentrations measured during the hospital stay
[18]. Of note is a correlation found for copeptin with maxi-
mal concentrations of hs-TnT in our study. This leads to
speculate, first, that this is the reason why hs-TnT measured
at admission had low prognostic value and, second, that
copeptin might be considered an early indirect predictor of
infarct size. The latter hypothesis was recently evaluated
and confirmed in a population of STEMI patients [19]. As
a consequence might be regarded the observation of predic-
tive value of copeptin for the development of heart failure,
with higher and diagnostic for HF levels of NT-proBNP
among patients stratified with copeptin, age, and GFR as
high risk. It was not reflected in the value of EF but it is
known that levels of NT-proBNP might be elevated also in
Table 2: The Cox regression model for death at 6 and 12 months.
Characteristic
At six months At one year
HR 95% CI p value HR 95% CI p value
Copeptin≥ 17.4 pmol/l 14.1 1.7–116.8 0.01 4.3 1.3–14.8 0.02
Age 1.3 1.1–1.5 0.001 1.1 1.04–1.2 0.002
Male sex 0.2 0.04–1.1 0.06 0.6 0.2–1.9 0.359
Diagnosis of NSTEMI 3.0 0.4–24.7 0.31 2.3 0.5–10.8 0.281
Prior AMI 1.0 0.2–5.0 0.96 1.4 0.4–4.8 0.591
Diabetes mellitus 1.1 0.2–5.8 0.89 1.1 0.3-4.1 0.909
GFR 0.9 0.86–0.95 <0.001 0.99 0.9–0.95 <0.001
EF 1.0 0.9–1.0 0.09 0.95 0.9–0.99 0.026
Admission NYHA class 3 or 4 7.7 1.3–46.1 0.03 11.8 1.9–72 0.008
Hs-TnT≥ 14 ng/l at admission 33.6 0.03–366,658 0.33 4.1 0.5–32.3 0.176
Hs-TnT mx 1.0 0.99–1.0 0.82 1.0 0.99–1.0 0.642
AMI: acute myocardial infarction; CI: confidence interval; EF: ejection fraction; GFR: glomerular filtration ratio; GRACE: Global Registry of Acute Coronary
Events; HR: hazard ratio; hs-TnTmx: maximal concentration of high-sensitive troponin T; NSTEMI: non-ST segment elevation myocardial infarction; NYHA:
New York Heart Association.
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patients with preserved EF [20]. We would like, however, to
prevent the reader from interpreting our results as a prove of
direct relationship between copeptin and infarct size and/or
heart failure and consider them as a hypothesis that warrants
further research.
In conclusion, copeptin appears to be an independent
predictor of long-term mortality in a selected population of
patients suspected for an ACS. In addition, copeptin may
be considered as an early marker for the identification of
patients at higher risk of the development of HF at long term
in this population. The outcomes warrant a confirmation in a
larger cohort.
4.1. Limitations. The following limitations should be men-
tioned. The observational character of the study limits the
interpretation of clinical benefit from risk assessment with
copeptin. Further, studied troponin was the hs-TnT (Roche).
It remains unknown if the use of other assays or other tropo-
nin would influence the outcomes. Next, in the study, we
used a prespecified cutoff for copeptin at the 97.5th percen-
tile, as the closest to that recommended by the guidelines
(99th percentile) that was available from the manufacturer’s
resources; therefore, the outcomes are limited with regard
to previously proposed values [6, 11]. Further studies are
warranted to directly compare different cutoffs to identify
the optimum for prognostic purposes.
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